The Mark Foundation is thrilled to announce our 2026 Momentum Fellows! 🚀 We are supporting 9 brilliant investigators—4 new recipients & 5 renewals—tackling everything from immunosuppression to CAR-T cell exhaustion. Meet the future of cancer research: themarkfoundation.org/2026/02/the-...

Huge congratulations to Mark Foundation grantees Catherine Wu & Darrell Irvine for being named to the 2026 @Time 100 Health list! 🏆 🧬Learn how their work is redefining the future of oncology. themarkfoundation.org/blog/56202/ #TIME100 #CancerResearch

📢 In partnership with the Sontag Foundation, @braintumor.org, the Southeastern Brain Tumor Foundation, the Uncle Kory Foundation & Fondation Anne et Claude Berda, we're committing new funding to 5 teams tackling the world’s most aggressive brain tumor. 🧠🧬 themarkfoundation.org/2026/02/the-...

We are proud to join forces with a new coalition of leading organizations including @theaacr.bsky.social, @break-cancer.bsky.social, @lustgarten.org & @themarkfdn.bsky.social! Together we will fund $12mm to 6 teams focused on early detection of some of the most challenging cancers including ovarian.

📢 Announcing the 2026 Early Detection Award recipients! 📢 In partnership with @theaacr.bsky.social, @lustgarten.org, @break-cancer.bsky.social, and @tinaswish.bsky.social, we are committing $12 million to 6 teams developing new diagnostic approaches for the world’s deadliest cancers. 🧬🔬

In an increasingly uncertain funding environment, how can philanthropy effectively support cancer research? In After Treatment, CEO Ryan Schoenfeld tells @grogowl.bsky.social how The Mark Foundation continues to advance game-changing science. www.after-treatment.com/p/where-is-t...

Honored to receive the EACR Rising Star Award 2026. Thanks to @helloeacr.bsky.social, @themarkfdn.bsky.social, and the Pezcoller Foundation for the support. This backs a vision we deeply believe in: time-resolved dynamics are key in cancer–immune interactions. tinyurl.com/45vpm3rr

Congratulations to Daniel Birschenkaum of @dkfz.bsky.social, the 2026 recipient of the @helloeacr.bsky.social-Mark Foundation-Pezcoller Rising Star Award! The award will support his work exploring the dynamic behavior of immune cells in brain tumors. themarkfoundation.org/2026/01/dani...

🚨 New research from the CancerGrand Challenges SPECIFICANCER team (co-funded by The Mark Foundation & @cancerresearchuk.org) highlights NPM1 as a promising target for bowel & liver cancer. Read more in @the-independent.com: www.independent.co.uk/news/health/...

Congratulations to Mark Foundation Scientific Advisory Committee chair and Board member @rosslevinemd.bsky.social !

📢 Announcing The Mark Foundation 2026 Emerging Leader Award winners! 📢 We are committing $3.75 million to 5 visionary early-career scientists poised to lead the next generation of oncology breakthroughs. We can't wait to see their impact! themarkfoundation.org/2026/01/2026...

We're back from the @theaacr.bsky.social Special Conference on Early Onset Cancers! A major highlight was the update from Mark Foundation-Waxman Foundation grantee Ashani Weeraratna on her research into how the aging tumor immune microenvironment influences tumor progression. #AACRearlyonset25

What happens when the scientist becomes the subject? Emerging Leader Award winner Ansuman Satpathy & collaborator Caleb Laureau are challenging conventional wisdom in genetics using findings from Satpathy’s own DNA. themarkfoundation.org/blog/the-sci...

📢 New Impact Report from SPECIFICANCER, the team unravelling one of cancer biology’s hardest puzzles: tissue specificity. A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science. 🔗 lnkd.in/dQC-iHmK

The Mark Foundation scientific community will be well represented at #ASH25! Heading to Orlando? Don't miss these presentations, moderated sessions, and posters from our grantees. themarkfoundation.org/blog/mark-fo...

From bench to bedside! In a Phase 1 trial, a vaccine targeting a neoantigen in fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer primarily affecting younger people, showed significant clinical benefit when combined with immune checkpoint inhibitors. www.nature.com/articles/s41...

Every day counts in the fight against cancer—and we can’t afford to let reduced federal funding slow progress. Your support this #GivingTuesday helps The Mark Foundation fund ambitious science and bring breakthroughs to the patients who need them. themarkfoundation.org/donate/

Read the newly published impact report from the SPECIFICANCER team that reshaped our understanding of tissue specificity. Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science. 🔗 lnkd.in/eDrQ9guu

What a wonderful few days we've had together in Bergamo at The Rise of Early-Onset Cancers 🎉 Thank you to everyone who attended, our co-organisers @themarkfdn.bsky.social and to the Scientific Programme Committee for all the dedication they put into the great science showcased in the conference!

Members of NexTGen (co-funded by @themarkfdn.bsky.social), Nikolaos Sgourakis & John Maris, contributed to a new Nature paper from David Baker’s lab showing AI-designed antibodies with atomic-level precision A potential game-changer 👉 nature.com/articles/s41586-025-09721-5

It's been a productive 3 days in Bergamo, Italy, at the @helloeacr.bsky.social - Mark Foundation Joint Conference: The Rise of Early-Onset Cancers! Participants have shared new insights into the rise in cancer among young patients & identified paths forward for prevention, detection, & treatment.

Prof. Sir Mike Stratton delivers his keynote lecture at the close of The Rise of Early-Onset Cancers in Bergamo. We're very grateful for the partnership of @themarkfdn.bsky.social in this groundbreaking joint conference, which has explored a critical and underexplored frontier in cancer biology.

We're so grateful to our partners at the @themarkfdn.bsky.social for supporting the NexTGen team and helping to make their research possible. Thank you to all our #CancerGrandChallenge partners who make progress possible 👏

The @theaacr.bsky.social–Mark Foundation Chemistry in Cancer Research Grants are now accepting Letters of Intent! We’re seeking bold, innovative approaches in chemistry and chemical biology to tackle the biggest challenges in cancer. Learn more and apply: www.aacr.org/grants/aacr-...

🎉Three members of The Mark Foundation’s community — @charlesswanton.bsky.social, Michel Sadelin, and Victor Velculescu — were elected to @nam.edu yesterday!🎉 Learn more about their remarkable achievements: themarkfoundation.org/blog/three-m...

New in @nature.com: ASPIRE awardee @loisher.bsky.social of @petermaccc.bsky.social shows that pregnancy & breastfeeding cause long-lasting immunological changes that significantly reduce breast cancer risk, especially for triple-negative breast cancer. themarkfoundation.org/blog/aspire-...

📢Calling all Mark Foundation grantees (past and current) & advisors! 📢 Check your inboxes - you should have received your invite to our 2026 Scientific Symposium. Haven't seen it? Send us a note at [email protected].

Huge congratulations to @rosslevinemd.bsky.social, who has been named @mskcancercenter.bsky.social's new Chief Scientific Officer! We’re deeply grateful to have his expertise on our Board of Directors and as Chair of our Scientific Advisory Committee. www.mskcc.org/news-release...

Why does immunotherapy rarely lead to a complete cure?| In @cellpress.bsky.social, ASPIRE awardee Charles Swanton tracks the lineages of tumor subclones & suggests that subclonal evolution allows some cells to evade immune attack. #CancerResearch #Immunology www.cell.com/cancer-cell/...

This collaborative project would not have be possible w/o JP and our wonderful colleagues (many not on social), and support from @damonrunyon.org and @themarkfdn.bsky.social!

The Emerging Leader Award program “lets people follow where the science goes,” says 2019 winner Andrew Lane. That flexibility has allowed him to bring discoveries from bench to bedside with impressive speed. Learn more in our 2024 Annual Report: 2024.themarkfoundation.org/an-emerging-...

A dual breakthrough in #CancerResearch: ASPIRE awardees Bennie Lemmens & Jira Bartek of @ki.se & @scilifelab.se developed tech to visualize DNA replication in stunning detail AND uncovered a key protein that acts as an “on-switch” for the replication process. themarkfoundation.org/blog/aspire-...

The Mark Foundation for Cancer Research is making a huge impact - in the US and globally 🙌 Very grateful for their support 🙏 - for an #ASPIRE award that funded our microbiome research, and for two #Momentum Fellows in our lab @lbejarano.bsky.social & @ale-matera.bsky.social @themarkfdn.bsky.social

$34.5 million in awarded grants. 7 new interventional trials. 212 peer-reviewed publications. Read our newly released 2024 Annual Report to catch up on our grantees’ achievements and discover how we’re accelerating progress in the fight against cancer.  2024.themarkfoundation.org

New in @nature.com: past ASPIRE Awardee Trudy Oliver identifies the likely origin of some SCLC tumors. This breakthrough discovery for an aggressive, hard-to-treat disease could enable therapies that target lineage plasticity—a major challenge in cancer. www.nature.com/articles/s41...

📣Introducing the Samuel Waxman Institute for Aging & Cancer! 📣 As today's NYTimes DealBook reports, the Samuel Waxman Cancer Research Foundation is joining us to launch a world-first institute focused on how the biology of aging drives cancer risk at all life stages. www.nytimes.com/2025/09/09/b...

Sometimes, research is personal. In @cp-neuron.bsky.social, Endeavor awardee Tobias Janowitz shares how his late mother’s experience with cancer-associated cachexia, a debilitating wasting syndrome, continues to shape his perspective and research. www.cell.com/neuron/fullt...

⏳Reminder: Letters of Intent for our next round of Endeavor Award funding are due next Wednesday, September 3! #ResearchFunding themarkfoundation.org/endeavor/

🎉Mark Foundation portfolio company Interius BioTherapeutics has been acquired by Kite Pharma!🎉 The move advances a game-changing in vivo CAR T-cell platform that originated with Saar Gill’s Emerging Leader Award project. themarkfoundation.org/2025/08/kite...

Yesterday we wrapped up a 2-day scientific review meeting for the Mark Foundation Center for Advanced Genomics and Imaging at ‪@jhu.edu‬. The Center’s brilliant scientists are driving breakthroughs in genomics, imaging & data science that will make immunotherapy effective for more patients.

Submissions are open for the EACR - @themarkfdn.bsky.social Postdoctoral Fellowships until 20 August! This funding is awarded for a period of three years to support excellent postdoctoral researchers in laboratories throughout Europe 🌍 Learn more: eacr.org/eacr-fellows...

Cancer-related cachexia is responsible for ~1/3 of cancer deaths, yet its causes & treatments have proven elusive—until now. In @cellpress.bsky.social, Endeavor Award team leader Ayelet Erez identifies a cause for the syndrome—and a path forward for patients. www.cell.com/cell/abstrac...

Do the types of dietary fats that patients consume impact cancer progression? In a new @nature.com paper, Emerging Leader Award winner @lydialynch.bsky.social shows that diets high in some types of fats suppress anti-tumor responses in patients with obesity. www.nature.com/articles/s42...

Could the same proteins that drive autoimmune disease help fight cancer? In @nature.com, Emerging Leader Award winner Aaron Ring of @fredhutch.bsky.social shows that some autoantibodies are linked to better patient outcomes with checkpoint inhibitor therapies. www.fredhutch.org/en/news/rele...

Amid widespread funding cuts, The Mark Foundation is creating a new operating system for cancer research. CEO Ryan Schoenfeld joined Sam Fazeli on the latest episode of the @bloomberg.com Vanguards of Health podcast to share how. Listen now: www.bloomberg.com/professional...

Great visit with our @salkinstitute.bsky.social Endeavor team! Co-PIs Reuben Shaw, Susan Kaech, Christian Metallo, & Alan Saghatelian & collaborators Christina Towers & Dannielle Engle updated us on their work identifying new metabolic targets in lung cancer. themarkfoundation.org/portfolio/id...

The Mark Foundation's Becky Bish and Ray DuBois just wrapped up a visit to MD Anderson — we’re always impressed by how they translate ground-breaking research to patient care! @mdanderson.bsky.social #cancerresearch

Could early-life mutagenic exposure to colibactin-producing bacteria be a driver in rising rates of #colorectalcancer? IARC-Mark Foundation Postdoctoral Fellow Wellington Oliveira dos Santos highlights a potential link in a new @nature.com ‪paper. www.nature.com/articles/s41...

Exciting progress in cancer treatment! 🎉Our portfolio company Interius BioTherapeutics is developing a novel lentiviral platform for in vivo CAR therapy. The approach could offer patients an “off the shelf” treatment option—& it doesn’t require pre-treatment chemo. www.cell.com/molecular-th...

I am so honored to be an awardee from a foundation that recognizes and funds innovation. I wish more foundations shared the Mark foundations vision. Also, the Pezcoller meeting was so fantastic this year, we were hardly the only highlights.